Vol 12, No 3 (2019)
Research paper
Published online: 2019-11-28
Blood count parameters in the course of multiple sclerosis
Journal of Transfusion Medicine 2019;12(3):109-116.
Abstract
Background. Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. It mostly affects young people. Pathological changes in MS cause destruction of myelin sheath around axons which impedes transmission of nerve impulses in the central nervous system. The diagnosis of MS is based on clinical evaluation, biochemical tests of blood and cerebrospinal fluid as well as imaging. The study aim was to assess blood counts of MS patients.
Materials and methods. The study group comprised 189 people (77 healthy) and 112 MS patients treated at the Department of Neurology at the Medical University in Lublin. Whole blood parameters were determined on the Advia 2120 i analyzer. Statistical analysis was made using the Statistica 12.5 program.
Results. Patients evaluated with regard to clinical condition and stage of disease demonstrate differences in RBC count, hemoglobin, hematocrit and red blood cell volume (MCV). RBC count of patients with relapsing-remitting MS (RRMS) was lower (Me = 4.73 million/μl) than for patients with secondary progressive MS (SPMS) (Me = 5.03 million/μl). Additionally, differences in hemoglobin were observed between RRMS patients (Me = 13.9 g/dl) and SPMS patients (Me = 14.7 g/dl). Significant differences were also observed for hematocrit; (Me = 40.5%) for RRMS patients and (Me = 44%) for SPMS patients. Differences in MCV between the examined groups of MS patients and the control group were not statistically significant. The same referred to differences in WBC count; (Me = 6.95 thousand/μl) for MS patients and (Me = 6.59 thousand/μl) for control group as well as platelet count; (Me = 237.5 μs/μl) for SM patients and (Me = 252 thousand/μl) for control group.
Conclusion. Analysis of blood parameters reveals significant differences between MS patients and control as well as differences between RRMS and SPMS patients with regard to red blood cell system. An in-depth analysis also in terms of disease duration and stage of clinical advancement may be a valuable source of information on the overall health condition of MS patients.
Keywords: multiple sclerosisblood countRBCWBCPLTHgb
References
- Sadovnick AD. Genetic epidemiology of multiple sclerosis: a survey. Ann Neurol. 1994; 36 Suppl 2: S194–S203.
- Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol. 2005; 252 Suppl 3: iii15–iii20.
- Amato MP, Ponziani G, Bartolozzi ML, et al. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci. 1999; 168(2): 96–106.
- Potemkowski A. Stwardnienie rozsiane w świecie i w Polsce – ocena epidemiologiczna. Aktualn Neurol. 2009; 9: 91–97.
- Bradburn J, Broughton S, Chadwick D. Royal College of Physicians of London: Multiple sclerosis. National clinical guideline for diagnosis and management in primary and secondary care. 2004; 8: 39–46.
- Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin. 2005; 23(1): 17–38, v.
- Rosiak K, Zagożdżon P. Czynniki środowiskowe w epidemiologii stwardnienia rozsianego. Probl Hig Epidemiol. 2012; 93(4): 627–631.
- Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993; 20(1): 17–29.
- Shabab T, Khanabdali R, Moghadamtousi SZ, et al. Neuroinflammation pathways: a general review. Int J Neurosci. 2017; 127(7): 624–633.
- Ebers M. Natural history of multiple sclerosis. W: Compston A. (red. ) Mc Alpine’s Multiple Sclerosis, New York, Churchill Livingstone. ; 1998: 191–221.
- Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016; 353(6301): 777–783.
- Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1984; 65(3): 135–138.
- Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry. 1992; 55(5): 341–346.
- Smelkowska A, Wilkiewicz M, Grabowska-Fudala B, et al. Course of Care of a Multiple Sclerosis Patient in the Context of Pharmacotherapy. PNN. 2015; 4: 130–137.
- Stuart WH. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management. J Manag Care Pharm. 2004; 10(3 Suppl B): S19–S25.
- Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83(3): 278–286.
- Selter RC, Hemmer B. Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther. 2013; 2: 21–30.
- Wender M. Biomarkery w stwardnieniu rozsianym. Aktualn Neurol. 2009; 9 (2), p. : 109–115.
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–173.
- Polman C, Reingold S, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology. 2005; 58(6): 840–846.
- Housley WJ, Pitt D, Hafler DA. Biomarkers in multiple sclerosis. Clin Immunol. 2015; 161(1): 51–58.
- Huang Y, Ying Z, Quan W, et al. The clinical significance of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in Guillain-Barré syndrome. Int J Neurosci. 2018; 128(8): 729–735.
- Demirci S, Demirci S, Kutluhan S, et al. The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int J Neurosci. 2016; 126(8): 700–706.
- Qin B, Ma N, Tang Q, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2016; 26(3): 372–376.
- Wekerle H. B cells in multiple sclerosis. Autoimmunity. 2017; 50(1): 57–60.
- Dziedzic A, Bijak M. Interactions between platelets and leukocytes in pathogenesis of multiple sclerosis. Adv Clin Exp Med. 2019; 28(2): 277–285.
- Akaishi T, Takahashi T, Nakashima I. Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis. J Neuroimmunol. 2018; 319: 37–40.
- Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003; 126(Pt 12): 2738–2749.
- Bonek R, Maciejek Z. Naturalny przebieg stwardnienia rozsianego. Aktualn Neurol. 2009; 9(2): 116–125.
- Bridel C, Beauverd Y, Samii K, et al. Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study. Neurol Neuroimmunol Neuroinflamm. 2015; 2(4): e123.
- Pastuszak Z, Stepien A, Tomczykiewicz K, et al. BLOOD COUNT IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH MITOXANTRONE IN SHORT TIME OBSERVATION. Acta Pol Pharm. 2016; 73(5): 1369–1373.
